Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for >  years prior to the time of registration; patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study; Note: prospective RAS testing is not required; however, if the results of previous RAS testing are known, they must be used in assessing eligibility
Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast
The subject has a history of another active cancer within the past  years except cervical cancer in situ, in situ carcinoma of the bladder, squamous or basal cell carcinoma of the skin or another in situ cancer that is considered cured by the investigator (e.g., in situ prostate cancer, breast DCIS).
Individuals with the following non-invasive cancers are eligible: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
Previous malignant disease (other than Merkel cell carcinoma) diagnosed within  years from day  of study treatment that could interfere with study endpoints or put patient safety at risk\r\n* (NOTE: Exception will be made for adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ [skin, bladder, cervical, colorectal, breast] or low grade prostatic intraepithelial neoplasia or grade  prostate cancer; any other neoplasm, which is adjudged by the treating investigator to have a low risk of recurrence during the study, could be enrolled only after written approval from the medical monitor)
Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for  years. Time frame exceptions include successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer, or other in situ cancers.
Patient treated for a cancer other than GIST within  years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for  years. (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ cancers.)
Prior history of solid tumor malignancy diagnosed within the last three () years of study enrollment excluding adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer, in situ breast cancer, in situ prostate cancer (patients must have shown no evidence of active disease for  years prior to enrollment)
History of prior cancer within <  years, except for basal cell or squamous cell carcinoma of the skin, cervical cancer in situ or other in situ carcinomas.
Previous malignant disease other than the target malignancy to be investigated in this trial within the last  years, with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ. Any prior cancer must not be getting active treatment and must be in continuous complete remission for at least  years.
Have a concurrent malignancy or have had another malignancy within  year prior to initiation of screening (with the exception of adequately treated basal or squamous cell carcinoma, melanoma in situ, early-stage prostate cancer (Ta-cNM), ductal carcinoma in situ of the breast or cervical carcinoma in situ)
Patients with secondary malignancy that requires active systemic therapy that will interfere with interpretation of efficacy or toxicity of selinexor; (Note: patients with basal or squamous skin carcinoma, cervical carcinoma in situ, localized breast cancer requiring hormonal therapy or localized prostate cancer [Gleason score <  are allowed])
Previous malignant disease (other than the target malignancy to be investigated in this trial) within the last  years; subjects with a history of cervical carcinoma in situ, superficial or no-invasive bladder cancer, or basal cell or squamous cell carcinoma in situ previously treated with curative intent are NOT excluded
Patients with another active cancer (excluding basal cell carcinoma, cervical carcinoma in situ or melanoma in situ); prior history of other cancer is allowed, as long as there was no active disease within the prior  years
Prior malignancy (other than in situ cervical cancer, or basal cell or squamous cell carcinoma of the skin), unless treated with curative intent and without evidence of disease for  years or longer
Note: the time requirement also does not apply to patients who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cancers including cervical cancer, breast cancer, melanoma, or other in situ cancers
No prior malignancy unless it was cured over  years ago; i.e. prostate cancer, or early stage (I-III) solid tumors. Patients with a prior basal skin cancer or squamous cell carcinoma of the skin or in situ cervical malignancy that have undergone curative treatment are excluded from this requirement.
History of another malignancy other than the study indication under this trial within  years of study enrollment. Does not apply to subjects who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, in situ breast cancer, or other in situ cancers.
History of a second primary cancer is allowed in the event the cancer is curatively resected and there is no evidence of recurrence/metastatic disease x  year; subjects who have a history of cervical or breast carcinoma in situ, localized prostate cancer, adequately treated basal cell or squamous cell carcinoma of the skin, or superficial bladder tumors (Ta, Tis & T) are also allowed
Active malignancy (other than colorectal carcinoma [CRC]) or a history of prior malignancy within the past  years. Adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ, other low grade lesions such as incidental appendix carcinoid, or any other cancer from which the patient has been disease and treatment free for two years are allowed. Prostate cancer patients on active surveillance are eligible
History of previous malignant disease within the last  years with the following exceptions: basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary or follicular thyroid carcinoma, and non-muscle invasive bladder cancer
Has a known history of prior malignancy except if the patient has undergone potentially curative therapy with no evidence of that disease recurrence for  years since initiation of that therapy; Note: the time requirement for no evidence of disease for  years does not apply to the NSCLC tumor for which a subject is enrolled in this trial; the time requirement also does not apply to subjects who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for  years or greater, unless approved by the protocol investigator / lead-sub-investigator
Any malignancies in the  years prior to Baseline, excluding basal cell carcinoma, in situ malignancy, low-risk prostate cancer, cervical cancer after curative therapy.
Invasive malignancy other than ameloblastoma within  years, excluding curatively treated basal cell carcinoma, and other highly curable cancers such as early stage cutaneous squamous cell carcinoma (T NO) cervical carcinoma in situ (CIS), early stage prostate cancer, thyroid cancer, breast cancer, or history of malignancy with confirmed activating RAS mutation at any time
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for  years or greater, unless approved by the protocol chair or co-chair
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for  years or greater, unless approved by the protocol sponsor-investigator/lead-sub-investigator
History of a malignancy for which potentially curative treatment has been completed, with no evidence of malignancy for  years excepting successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, or in situ cervical cancer
Patient has a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the patient has undergone potentially curative therapy with no evidence of that disease for five years\r\n* Note: the time requirement also does not apply to patients who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cancers including cervical cancer, breast cancer, melanoma, or other in situ cancers
History of another malignancy other than the study indication under this trial within  years of study enrollment; does not apply to subjects who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, in situ breast cancer, or other in situ cancers\r\n* Exception: patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study; prospective RAS testing is not required; however, if the results of previous RAS testing are known, they must be used in assessing eligibility
No other malignancy within past five years except basal cell carcinoma of the skin, cervical carcinoma in situ, or non-metastatic prostate cancer
History of current diagnosis of other cancer except curative cervical cancer in situ, basal or squamous cell carcinoma of the skin
Patients with a history of prior secondary malignancy that requires active systemic therapy that will interfere with interpretation of efficacy or toxicity of IMMU-, or limit survival to  years. These patients should be discussed with the sponsor prior to enrollment. Patients with basal or squamous skin carcinoma, cervical carcinoma in situ on biopsy, localized breast cancer requiring hormonal therapy or localized prostate cancer (Gleason score < ) do not require discussion.
A history of prior malignancy. Subjects with a history of basal or squamous cell carcinoma of the skin, superficial bladder cancer, or in situ cervical cancer, or those that have received curative therapy with no disease recurrence for ?  years, may be enrolled.
Patient with other malignancies from which the patient has been continuously disease-free for <  years, with the exception of melanoma, cervical carcinoma in situ, basal cell or squamous cell skin cancer, ductal or lobular carcinoma in situ of the breast
Patient treated for a cancer other than GIST within  years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
Known history of other malignancy unless having undergone curative intent therapy without evidence of that disease for ?  years except cutaneous squamous cell and basal cell skin cancer, superficial bladder cancer, in situ cervical cancer or other in situ cancers are allowed if definitively resected.
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for  years or greater, unless approved by the protocol chair or co-chair
Known additional malignancy within the past  years; exceptions include treated localized basal cell or squamous cell carcinoma of the skin, in situ cervical or vulvar carcinoma that has undergone potentially curative therapy, superficial bladder tumors (Ta, Tis & T), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer (Gleason sore ); any cancer curatively treated >  years prior to registration with no clinical evidence of recurrence is permitted
Participant is <  years free of another primary malignancy; exceptions include basal cell skin cancer, stage -I squamous cell cancer of the skin, cervical carcinoma in situ, anal carcinoma in situ
Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for >  years prior to the time of randomization
Patient has a history of a prior malignancy within the past  years (excluding resected basal cell carcinoma of the skin or in situ cervical cancer)
Patients who have other current malignancies are not eligible; patients with other malignancies are eligible if they have been continuously disease free for >  years prior to the time of randomization; patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ are eligible; patients with prior history of basal or squamous skin cancer are eligible; patients who have had multiple primary melanomas are eligible
Any malignancy that has not been in complete remission for at least  years\r\n* NOTE: patients with cured basal or squamous cell skin cancer are not excluded; patients with a history of excised in situ cancers, including breast, cervical, colon, superficial bladder, prostate or other body system are not excluded; study entry will be allowed at the discretion of the Principal Investigator\r\n* NOTE: recurrence of the in situ cancer or tumor at the time of study entry would be exclusionary
Patients who have other current malignancies are not eligible; patients with other malignancies are eligible if they have been continuously disease free for >  years prior to the time of randomization; one exception are patients treated with a curative intent and are continuously disease free for >  years; these patients would be considered eligible: \r\n* Patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ are eligible\r\n* Patients with prior history of basal or squamous skin cancer are eligible
Previous malignant disease (other than gastric cancer) within the last  years with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ (bladder, cervical, colorectal, breast)
Patients must not have any history of other cancer within  years from time of randomization with the exception of basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or resected non-invasive (Ta) urothelial carcinoma
Previous malignant disease (other than MCC) within the last  years with the exception of basal or squamous cell carcinoma of the skin and for Part A cervical carcinoma in situ or for Part B carcinoma in situ (skin, bladder, cervical, colorectal, breast or low grade prostatic intraepithelial neoplasia or Grade  prostate cancer)
Diagnosis of another invasive malignancy unless free of disease for at least three years following therapy with curative intent. Patients with early-stage basal cell or squamous cell skin cancer, cervical intraepithelial neoplasia, cervical carcinoma in situ, or superficial bladder cancer, may be eligible to participate at the Investigator's discretion.
History of other cancer type, except for cutaneous basal cell or squamous cell carcinoma, or cervical or prostate cancer in situ, within the last  years prior to CD
Other malignancies within the past  years except for the following: adequately treated cervical or vulvar carcinoma in situ, treated basal cell or squamous carcinoma of the skin, superficial bladder tumors (Ta, Tis & T), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer; any cancer curatively treated >  years prior to entry with no clinical evidence of recurrence is permitted
Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ
Patients with prior history of in situ cancer (e.g., breast, melanoma, squamous cells carcinoma of the skin, cervical).
Has a known additional malignancy within the past  years. Exceptions include treated localized basal cell or squamous cell carcinoma of the skin, in situ cervical or vulvar carcinoma that has undergone potentially curative therapy, superficial bladder tumors (Ta, Tis & T), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer (Gleason sore ). Any cancer curatively treated >  years prior to registration with no clinical evidence of recurrence is permitted
Other active solid malignancies within  years prior to randomization, except for basal cell or squamous cell skin cancer or in situ cervical or breast cancer or superficial melanoma
Have systemic collagen vascular disorder, systemic autoimmune disease, an organ transplant or diagnosis of cancer within  years other than CTCL (not including basal cell carcinoma, non-invasive squamous cell cancer of the skin, malignant melanoma in situ, or cervical carcinoma in situ)
History of other malignancies unless a.) the patient has undergone definitive treatment more than  years prior and is without evidence of recurrent malignant disease or b.) had basal or squamous cell carcinoma of the skin; superficial carcinoma of the bladder; carcinoma of the prostate with current prostat specific antigen < . ng/mL; ductal carcinoma in situ; or cervical intraepithelial neoplasia.
History of other prior malignancies except for properly treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer or early stage prostate cancer
Other active malignancies requiring chemotherapy treatment within  years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical or breast cancer or superficial, resected melanoma
Individuals with the following cancers are eligible if diagnosed and treated within the past  years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for >=  years prior to the time of randomization
Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for  years or greater, unless approved by the protocol principal investigators
Malignancy within  years or active disease requiring treatment other than the target cancer. The exceptions are prostate cancer (Gleason grade <  with normalized PSA levels), treated in situ cervical, breast carcinoma, squamous or basal cell skin cancer.
History of other malignancies within the past year except for treated basal cell or squamous cell skin cancer or in situ cervical cancer
Patient is =<  years free of another primary malignancy; exceptions include the following:\r\n* Cervical carcinoma in situ\r\n* Anal carcinoma in situ
Participant is =<  years free of another primary malignancy; exceptions include the following:\r\n* Basal cell skin cancer \r\n* Cervical carcinoma in situ\r\n* Anal carcinoma in situ
Patients who have other current malignancies are not eligible; patients with other malignancies are eligible if they have been continuously disease free for >  years prior to the time of registration; patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ are eligible; patients with prior history of basal or squamous skin cancer are eligible; patients who have had multiple primary melanomas are eligible
Patients who have other current malignancies are not eligible; patients with other malignancies are eligible if they have been continuously disease free for >  years prior to the time of randomization; patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia, or melanoma in situ are eligible; patients with a prior history of basal cell or squamous cell skin cancer are eligible; patients who have had multiple primary melanomas are eligible
Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial bladder cancer stage , from which the subject has not been disease-free for at least  years
Subjects with a history of prior malignancy other than HL, NHL, or MM that have not been in remission for > years, with the exception of basal cell or squamous cell carcinoma, cervical carcinoma in situ on biopsy, or localized prostate cancer (Gleason score <)
Active malignancy, other than the one for which the allogeneic mPB transplant is being performed, within  months of enrollment, excluding superficial basal cell and carcinoma in situ cervical cancer;
Participant has or has had other cancer(s) within  years of study; however, in situ breast, in situ cervical, and basal cell/squamous cell skin cancers are allowed
History of cancer (excluding basal cell carcinoma of the skin) including cervical cancer
History of baseline findings of: diabetes mellitus requiring insulin therapy; pancreatitis; hepatitis B, hepatitis C or HIV; malabsorption syndrome or inability to swallow or retain oral medicine; major surgery ?  days prior to enrollment; ECOG performance status ? ; or another cancer within  years except for basal carcinoma of the skin or cervical carcinoma in situ; any clinically significant and uncontrolled major morbidity
Have a history of other malignancy(ies) unless: They have been disease-free for at least  years and are deemed by the treating investigator to be at low risk for recurrence of that malignancy, or the only cancer they have had is cervical cancer in situ, or basal cell or squamous cell carcinoma of the skin
No prior history of other malignancies within past  years (besides breast cancer); individuals with the following cancers are eligible if diagnosed and treated within the past  years: ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin; no concurrent malignancy or other serious medical condition as deemed by the investigator; patients with history of contralateral breast cancer are not eligible
Patients with another active cancer (excluding basal cell carcinoma, cervical carcinoma in situ or melanoma in situ); prior history of other cancer is allowed, as long as there was no active disease within the prior  years
